4) Neurocrine Biosciences Inc. (NBIX) Sector: Healthcare Industry: Drug Manufacturers - Major Market Cap: $489.37M Beta: 0.35
Neurocrine Biosciences Inc. has a 5-Year Projected Earnings Per Share Growth Rate of 69.00%, a Return on Equity of 40.52%, and a Return on Assets of 19.65%. The short interest was 4.59% as of 06/17/2012. Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase II drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids.
Market Data 
Markets 
AI
